Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Gene Panel May Be Able to Identify Existing and Potential Alcoholics

By LabMedica International staff writers
Posted on 02 Jun 2014
A Convergent Functional Genomics (CFG) approach was used to discover genes involved in alcoholism in a study that has implications for genetic testing to assess risk for developing an illness before the illness manifests itself clinically.

The CFG technique was developed by Dr. More...
Alexander Niculescu of the Indiana University School of Medicine (Indianapolis, USA), and collaborators starting in 1999. It is an approach for identifying and prioritizing candidate genes and biomarkers for complex psychiatric and medical disorders by integrating and tabulating multiple lines of evidence including gene expression and genetic data from human studies and from animal model work. CFG generates a signal that is predictive and is reproducible in independent studies, as opposed to the fit-to-cohort aspect of classic human genetic studies like the genome-wide association study (GWAS), where the issue of genetic heterogeneity makes the top statistically significant findings from even large size studies less reproducible in independent studies.

In the current work, Dr. Niculescu and collaborators in the United States and Germany used CFG to analyze data from a German genome-wide study of alcoholism and data from a variety of other studies into genetic links to alcoholism. The analysis produced a group of 135 candidate genes. They then used a stress-reactive animal model of alcoholism, the D-box binding protein (DBP) knockout mouse, to identify genes expressed by both the alcoholic humans and the stress-reactive alcoholic mice.

This process yielded a panel of 11 genes with 66 single-nucleotide polymorphisms (SNPs). The investigators found that this panel of 11 genes could be used to differentiate between alcoholics and non-alcoholics in three different research populations for which genetic data and information about alcohol consumption were available: a group of Caucasian subjects and a group of African American subjects from the USA, and a third group from Germany.

"This powerful panel of just 11 genes successfully identified who has problems with alcohol abuse and who does not in tests in three patient populations on two continents, in two ethnicities and in both genders," said senior author Dr. Alexander B. Niculescu, associate professor of psychiatry and medical neuroscience at the Indiana University School of Medicine. "We believe this is the strongest result to date in the field of alcoholism and offers a comprehensive—though not exhaustive—window to the genetics and biology of alcoholism."

The study was published in the May 20, 2014, issue of the journal Translational Psychiatry.

Related Links:

Indiana University School of Medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.